Takeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest Down 24.4% in January

Takeda Pharmaceutical Company Limited (NYSE:TAK) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 3,710,000 shares, a drop of 24.4% from the December 31st total of 4,910,000 shares. Based on an average daily volume of 1,710,000 shares, the short-interest ratio is presently 2.2 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TAK. Hexagon Capital Partners LLC raised its position in shares of Takeda Pharmaceutical by 34.3% in the third quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock worth $63,000 after acquiring an additional 1,129 shares during the period. Gold Investment Management Ltd. raised its position in shares of Takeda Pharmaceutical by 2.0% in the third quarter. Gold Investment Management Ltd. now owns 73,204 shares of the company’s stock worth $1,049,000 after acquiring an additional 1,428 shares during the period. Smithfield Trust Co raised its position in shares of Takeda Pharmaceutical by 76.9% in the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after acquiring an additional 1,490 shares during the period. Kovitz Investment Group Partners LLC raised its position in shares of Takeda Pharmaceutical by 7.0% in the third quarter. Kovitz Investment Group Partners LLC now owns 25,456 shares of the company’s stock worth $362,000 after acquiring an additional 1,670 shares during the period. Finally, Aaron Wealth Advisors LLC raised its position in shares of Takeda Pharmaceutical by 7.2% in the fourth quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company’s stock worth $331,000 after acquiring an additional 1,670 shares during the period. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock traded down $0.30 during trading on Friday, hitting $13.41. 2,315,201 shares of the company’s stock were exchanged, compared to its average volume of 1,807,006. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.77 and a current ratio of 1.28. The business has a 50-day simple moving average of $13.31 and a 200-day simple moving average of $13.89. Takeda Pharmaceutical has a 52-week low of $12.57 and a 52-week high of $15.08. The stock has a market capitalization of $42.65 billion, a price-to-earnings ratio of 23.11, a PEG ratio of 0.25 and a beta of 0.51.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 6.49% and a return on equity of 10.00%. On average, research analysts forecast that Takeda Pharmaceutical will post 1.55 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.